Skip to main content
PMC home page
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2020 Dec 2;38(3):265–272. doi: 10.4103/ijmm.IJMM_20_330

Effect of Chloroquine and Hydroxychloroquine on COVID-19 Virological Outcomes: An Updated Meta-Analysis

Rashmi Ranjan Das **,*, Bijayini Behera **, Baijayantimala Mishra **, Sushree Samiksha Naik 1
PMCID: PMC7709583  PMID: 33154234

Abstract

As anti-malarial drugs have been found to inhibit Corona viruses in vitro, studies have evaluated the effect of these drugs inCOVID-19 infection. We conducted an updated meta-analysis of clinical trials and observational studies published till June 2020. Patients with reverse transcription polymerase chain reaction (RT-PCR) confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19) infection were included. The drugs used in the intervention group are Chloroquine (CQ)/Hydroxychloroquine (HCQ) with or without Azithromycin. The primary outcome is time to achieve virological cure. Of 1040 citations, 11 studies provided data of 1215 patients. Compared to control, CQ/HCQ has no significant effect on the time to negative COVID-19 RT-PCR results, neither in clinical trials (mean difference [MD] 1.55; 95% confidence interval [CI] - 0.7 to 3.79; P = 0.18; n = 180), nor in observational studies (MD 1.14; 95%CI - 11.98 to 14.26; P = 0.86, n = 407). CQ/HCQ did not affect the virological cure after day 3, 7, 10, 14, 21 and 28; except after day 5, as shown by a single small non-randomised trial (odds ratio [OR] 9.33; 95% CI 1.51 to 57.65; P = 0.02, n = 30). Pooled data from 2 observational studies showed a significant effect of CQ/HCQ on virological cure by after day 10 (OR 7.86; 95% CI 4.4 to 14.04, P < 0.001, n = 373) and day 14 (OR 6.37; 95% CI 3.01 to 13.48, P < 0.001, n = 407). The GRADE evidence generated was of “very low-quality/certainty”. To conclude, CQ/HCQ does not affect the time to virological cure compared to usual/standard of care in COVID-19 infection. Recurrent infection in a smaller number of patients was noted in the CQ/HCQ group. As the evidence generated was of “very low-quality/certainty)”, large good quality studies are needed to confirm the present findings.

Keywords: Aminoquinoline, azithromycin, COVID-19, evidence-based medicine, hydroxychloroquine, severe acute respiratory syndrome coronavirus 2

References

  • 1.Wu Z, McGoogan JM. Characteristics of and important lessons from thecoronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA 2020; 10.1001/jama.2020.2648. [published online ahead of print, 2020 Feb 24].
  • 2.COVID-19 in India. Available from: https://www.mohfw.gov.in/. [Last accessed on 2020 June 15].
  • 3.Saber-Ayad M, Saleh MA, Abu-Gharbieh E. The rationale for potential pharmacotherapy of COVID-19. Pharmaceuticals (Basel) 2020;13:96. doi: 10.3390/ph13050096. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M. Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56:105949. doi: 10.1016/j.ijantimicag.2020.105949. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Das RR, Jaiswal N, Dev N, Jaiswal N, Naik SS, Sankar J. Efficacy & safety of anti-malarial drugs (Chloroquine, and Hydroxy-chloroquine) in treatment of COVID-19 infection: A systematic review & meta-analysis. Front Med. 2020;7:482. doi: 10.3389/fmed.2020.00482. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Keyaerts E, Li S, Vijgen L, Rysman E, Verbeeck J, Ranst MV. Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice. Antimicrob Agents Chemother. 2009;53:3416–3421. doi: 10.1128/AAC.01509-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2:69. doi: 10.1186/1743-422X-2-69. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS coronavirus. J Virol. 2020;94:e00127-20. doi: 10.1128/JVI.00127-20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–273. doi: 10.1038/s41586-020-2012-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: What to expect for COVID-19? Int J Antimicrob Agents. 2020;55:105938. doi: 10.1016/j.ijantimicag.2020.105938. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Golden EB, Cho HY, Hofman FM, Louie SG, Schönthal AH, Chen TC. Quinoline-based antimalarial drugs: A novel class of autophagy inhibitors. Neurosurg Focus. 2015;38:E12. doi: 10.3171/2014.12.FOCUS14748. [DOI] [PubMed] [Google Scholar]
  • 12.Gbinigie K, Frie K. Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review. BJGP Open. 2020;4 doi: 10.3399/bjgpopen20X101069. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Clin Infect Dis. 2020;71:732–739. doi: 10.1093/cid/ciaa237. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Sahraei Z, Shabani M, Shokouhi S, Saffaei A. Aminoquinolines against coronavirus disease 2019 (COVID-19): Chloroquine or hydroxychloroquine. Int J Antimicrob Agents. 2020;55:105945. doi: 10.1016/j.ijantimicag.2020.105945. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Chen J, Liu D, Liu L, Liu P, Xu Q, Xia L. A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020;49:215–219. doi: 10.3785/j.issn.1008-9292.2020.03.03. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: Open label, randomised controlled trial. BMJ. 2020;369:m1849. doi: 10.1136/bmj.m1849. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Huang M, Tang T, Pang P, Li M, Ma R, Lu J. Treating COVID-19 with Chloroquine. J Mol Cell Biol. 2020;12:322–325. doi: 10.1093/jmcb/mjaa014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Borba M, de Almeida Val F, Sampaio VS, Alexandre MAA, Melo GC, Brito M. Effect of high vs. low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: A randomized clinical trial. JAMA Netw Open. 2020;3:e208857. doi: 10.1001/jamanetworkopen.2020.8857. [DOI] [PubMed] [Google Scholar]
  • 19.Huang M, Li M, Xiao F, Pang P, Liang J, Tang T. Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19. Natl Sci Rev. 2020:nwaa113. doi: 10.1093/nsr/nwaa113. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Mallat J, Hamed F, Balkis M, Mohamed MA, Mooty M, Malik A, et al. Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease: A retrospective study. medRxiv 2020.04.27.20082180;doi: 10.1101/2020.04.27.20082180. [DOI] [PMC free article] [PubMed]
  • 21.Chen Z, Hu J, Zhang Z, Jiang S, Han S, Yan D, et al. Efficacy of hydroxychloroquine in patients with COVID-19: Results of a randomized clinical trial. medRxiv 2020.03.22.20040758;doi: 10.1101/2020.03.22.20040758. [DOI]
  • 22.Chen X, Zhang Y, Zhu B, Zeng J, Hong W, He X, et al. Associations of clinical characteristics and antiviral drugs with viral RNA clearance in patients with COVID-19 in Guangzhou, China: A retrospective cohort study. medRxiv 2020.04.09.20058941;doi: 10.1101/2020.04.09.20058941. [DOI]
  • 23.Feng Z, Li J, Yao S, Yu Q, Zhou W, Mao Z, et al. The use of adjuvant therapy in preventing progression to severe pneumonia in patients with coronavirus disease 2019: A multicenter data analysis. medRxiv 2020; medRxiv 2020.04.08.20057539;doi: 10.1101/2020.04.08.20057539. [DOI]
  • 24.Shabrawishi MH, Naser AY, Alwafi H, Aldobyany AM, Touman AA. Negative nasopharyngeal SARS-CoV-2 PCR conversion in Response to different therapeutic interventions. medRxiv 2020; medRxiv 2020.05.08.20095679; doi: 10.1101/2020.05.08.20095679. [DOI] [PMC free article] [PubMed]
  • 25.Sarma P, Kaur H, Kumar H, Mahendru D, Avti P, Bhattacharyya A. Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis. J Med Virol. 2020;92:776–785. doi: 10.1002/jmv.25898. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.China National Health Commission. Chinese Clinical Guidance for COVID-19 Pneumonia Diagnosis and Treatment (7th edition), updated on; 16 March 2020. Available from: http://kjfy.meetingchina.org/msite/news/show/cn/3337.html. [Last accessed 2020 Jun 14].
  • 27.Higgins JP, Altman DG, Gøtzsche PC, Juni P, Moher D, Oxman AD. The cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:D5928. doi: 10.1136/bmj.d5928. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle Ottawa scale (NOS) for assessing the Quality of Nonrandomised Studies in Meta-Analysis. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxfordasp. [Last accessed on 2020 Apr 22].
  • 29.Sterne JA, Hernán MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M. ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:I4919. doi: 10.1136/bmj.i4919. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Review Manager (RevMan) Computer program. Ver. 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2014. [Last accessed on 2020 Apr 22] https://training.cochrane.org/online-learning/core-software-cochrane-reviews/revman.
  • 31.Schmidt FL, Oh IS, Hayes TL. Fixed- versus random-effects models in meta-analysis: Model properties and an empirical comparison of differences in results. Br J Math Stat Psychol. 2009;62:97–128. doi: 10.1348/000711007X255327. [DOI] [PubMed] [Google Scholar]
  • 32.Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0. The Cochrane Collaboration; 2008. Available from: http://www.cochrane-handbook.org. [Last accessed on 2020 Jun 14].
  • 33.GRADEpro GDT: GRADEpro Guideline Development Tool Software. McMaster University, 2015 (developed by Evidence Prime, Inc.). Available from: http://gradepro.org. [Last accessed 0n 2020 Apr 22].
  • 34.Schünemann H, Brożek J, Guyatt G, Oxman A, editors. GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations. Updated October 2013. The GRADE Working Group; 2013. Available from: http://guidelinedevelopment.org/handbook. [Last accessed 2020 Apr 22].
  • 35.Harper SA, Bradley JS, Englund JA, File TM, Gravenstein S, Hayden FG. Expert Panel of the Infectious Diseases Society of America. Seasonal influenza in adults and children–diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: Clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:1003–1032. doi: 10.1086/604670. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Touret F, de Lamballerie X. Of chloroquine and COVID-19. Antiviral Res. 2020;177:104762. doi: 10.1016/j.antiviral.2020.104762. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Indian Journal of Medical Microbiology are provided here courtesy of Elsevier

RESOURCES